Shots:
- AmacaThera has entered into an exclusive global license agreement with Pacira to develop & commercialize AMT-143, a long-acting non-opioid anesthetic, leveraging AmacaThera’s tunable hydrogel platform to treat post-operative pain
- As per the deal, AmacaThera & Pacira will jointly advance AMT-143, with AmacaThera leading select clinical studies & Pacira funding development through commercialization. In exchange, AmacaThera will receive $5M upfront & ~$225M in development & sales-based milestones, plus tiered royalties
- Both companies plan to begin a P-II trial in 2026, after which Pacira will assume full responsibility for the development, manufacturing, & commercialization of AMT-143
Ref: PRNewsWire| Image: AmacaThera & Pacira | Press Release
Related News:- Ailux Collaborates with Eli Lilly to Accelerate Bispecific Antibody Development
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
